 |
 |
 |
 |
 |
 |
|
|
ABIOMED Home > News > ABIOMED Announces Completion of Its Acquisition of Impella CardioSystems AG |
||||||||||||
 |
||||||||||||||
| ABIOMED Announces Completion of Its Acquisition of Impella CardioSystems AG | ||||||||||||||
| DANVERS,
Mass. (May 10, 2005) - ABIOMED, Inc. (NASDAQ: ABMD) a manufacturer
of products for circulatory care and support, today announced the
completion of its acquisition of Impella CardioSystems AG, a privately
held company located in Aachen, Germany, as of May 10, 2005. ABIOMED
has acquired all of the outstanding capital stock of Impella for approximately
4.04 million shares of ABIOMED common stock and approximately $1.8
million in cash. As previously announced, ABIOMED may also make additional
contingent payments to Impella shareholders based on stock price performance,
unit sales and FDA approval milestones. The contingent payments range
on a scale from zero dollars to approximately $29 million.
About ABIOMED About Impella CardioSystems AG This Release contains forward-looking statements, including statements regarding the Impella transaction, the development of ABIOMED's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including difficulties in integrating the newly acquired business and new personnel into our existing operations, undisclosed or unanticipated expenses or liabilities associated with the acquisition, acquisition costs, uncertainties associated with development, testing and related regulatory approvals, anticipated future earnings or losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events. ### Media Contact: Investor Relations Contact: |
||||||||||||||
